青少年与年轻成人SARS-CoV-2感染与BNT162b2接种后的心脏结局:400万人队列研究
倾向评分匹配后,感染组心肌炎、心包炎和死亡风险均显著高于未感染组;直接比较显示接种疫苗相比感染的心肌炎风险低85%、心包炎风险低79%、死亡风险低72%。
要点
- 感染未接种组心肌炎累积发生率最高(0.116%)。
- 匹配后感染 vs 未感染:心肌炎RR=4.91(95%CI 3.11-7.77)。
- 接种 vs 感染:心肌炎风险低85%,心包炎低79%,死亡低72%。
核心结论
- 记录到的SARS-CoV-2感染与青少年和年轻成人短期心肌炎、心包炎和全因死亡风险高于记录到的BNT162b2接种相关。
- 这些发现支持BNT162b2疫苗接种相对于确诊感染的有利获益-风险特征,但观察性全因死亡比较应解释为描述性而非因果性。
研究设计与样本
- 分为未感染/未接种(n=3,572,000)、感染/未接种(n=248,546)、接种/未感染(n=241,152)或混合免疫(n=10,677)四组。
- 采用竞争风险分析、倾向评分匹配和Cox回归,并进行性别分层分析,评估6个月结局。
主要发现
- 感染/未接种组心肌炎累积发生率最高(0.116%)。
- 1:1倾向评分匹配后,SARS-CoV-2感染相对于无感染与心肌炎风险显著升高相关(RR=4.91;95%CI=3.11-7.77)。
- 感染相对于无感染与心包炎风险显著升高相关(RR=1.93;95%CI=1.39-2.67)。
- 感染相对于无感染与死亡风险显著升高相关(RR=1.33;95%CI=1.04-1.71)。
- 直接比较中,接种相对于感染与心肌炎风险低85%、心包炎风险低79%、死亡风险低72%相关,保护作用在各性别中一致。
关键数值与推荐
- 心肌炎绝对风险差为0.0354%,相当于接种/未感染组相比感染/未接种组每2827人中少记录一例心肌炎事件。
临床怎么用
- 在青少年和年轻成人中,BNT162b2疫苗接种相对于SARS-CoV-2感染具有更有利的心脏不良结局风险特征。
- 与患者和家属沟通疫苗获益-风险时,可参考感染后心肌炎、心包炎和死亡风险高于接种后的证据。
局限性
- 观察性全因死亡比较应解释为描述性而非因果性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concerns about myocarditis and mortality after COVID-19 vaccination in pediatrics persist despite limited direct comparisons with SARS-CoV-2 infection risks. We compared risks of myocarditis, pericarditis, and mortality between infection and BNT162b2 vaccination in adolescents and young adults. METHODS: This retrospective cohort study used TriNetX data (December 2020-September 2025) for 4,072,375 individuals aged 16-25 years, categorized as uninfected/unvaccinated (n = 3,572,000), infected/unvaccinated (n = 248,546), vaccinated/uninfected (n = 241,152), or hybrid immunity (n = 10,677). We used competing risk analysis, propensity-score matching, and Cox regression, and sex-stratified analyses to assess 6-month outcomes. FINDINGS: The infected/unvaccinated group had the highest cumulative incidence of myocarditis (0.116%). After 1:1 propensity-score matching, SARS-CoV-2 infection was associated with significantly higher risks of myocarditis (relative risk [RR] = 4.91; 95%CI = 3.11-7.77), pericarditis (RR = 1.93; 95%CI = 1.39-2.67), and mortality (RR = 1.33; 95%CI = 1.04-1.71) versus no infection. In direct comparison, vaccination was associated with 85% lower myocarditis risk, 79% lower pericarditis risk, and 72% lower mortality versus infection. Protection was consistent across sexes. The absolute risk difference for myocarditis was 0.0354%, corresponding to one fewer recorded myocarditis event per 2827 individuals in the vaccinated/uninfected group compared with the infected/unvaccinated group. INTERPRETATION: Recorded SARS-CoV-2 infection was associated with higher short-term risks of myocarditis, pericarditis, and all-cause mortality than recorded BNT162b2 vaccination in adolescents and young adults. These findings support a favorable benefit-risk profile for BNT162b2 vaccination relative to documented infection, although the observational all-cause mortality comparison should be interpreted as descriptive rather than causal.
引用
- Toraih EA, Hussein MH, Thomas SJ, et al. Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals. Vaccine. 2026. PMID: 42607625. doi:10.1016/j.vaccine.2026.129001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。